Recombinant Human DEFb1 protein

中文名： 防御素β1(DEFb1)重组蛋白
别名： DEFb1；BD1；HBD1；Beta-defensin 1

货号: PA1000-4459

Price： ￥询价

20μg 50μg 100μg ＞100μg

数量：

大包装询价

产品详情

纯度	>95%SDS-PAGE.
种属	Human
靶点	DEFb1
Uniprot No	P60022
内毒素	< 0.01EU/μg
表达宿主	E.coli
表达区间	22-68aa
氨基酸序列	GNFLTGLGHR SDHYNCVSSG GQCLYSACPI FTKIQGTCYR GKAKCCK
预测分子量	5.1 kDa
蛋白标签	His tag N-Terminus
缓冲液	PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
稳定性 & 储存条件	Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.
复溶	Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.

参考文献

以下是关于DEFb1(人β-防御素1)重组蛋白的3篇代表性文献摘要，供参考：

---

1. **文献名称**：*Recombinant human beta-defensin-1 promotes endotoxin clearance and enhances bacterial killing in sepsis*

**作者**：Chen et al. (2020)

**摘要内容**：研究通过大肠杆菌系统成功表达rhDEFb1.证明其能通过结合内毒素(LPS)减轻脓毒症小鼠的炎症反应，并增强巨噬细胞对革兰氏阴性菌的吞噬作用。

2. **文献名称**：*Expression and functional characterization of recombinant human β-defensin-1 in yeast*

**作者**：Li et al. (2018)

**摘要内容**：利用毕赤酵母表达系统高效分泌表达rhDEFb1.验证其抗菌活性(对大肠杆菌和金黄色葡萄球菌的抑制作用)，并优化纯化工艺以提高蛋白产量。

3. **文献名称**：*Structural insights into the role of DEFb1 in mucosal immunity*

**作者**：Wang & Zhang (2016)

**摘要内容**：通过重组DEFb1的晶体结构分析，揭示其与呼吸道黏膜细胞表面受体的相互作用机制，提出其通过激活TLR4通路增强上皮屏障功能的分子基础。

---

注：以上文献信息为基于公开研究方向的模拟示例，实际文献需通过学术数据库(如PubMed、Web of Science)检索确认。建议使用关键词“recombinant DEFb1”、“human beta-defensin 1 expression”进行精准查询。

背景信息

**Background of Recombinant DEFb1 Protein**

Recombinant DEFb1 (Human Beta-Defensin 1) is a synthetic version of the naturally occurring antimicrobial peptide encoded by the *DEFB1* gene in humans. Defensins are small cationic peptides integral to innate immunity, acting as first-line defenders against pathogens. DEFb1. a member of the β-defensin family, is constitutively expressed in epithelial cells lining mucosal surfaces, skin, and organs like the kidneys and lungs. Its primary role involves disrupting microbial membranes through electrostatic interactions, neutralizing bacteria, fungi, and enveloped viruses. Additionally, DEFb1 exhibits immunomodulatory functions, such as recruiting immune cells (e.g., dendritic cells, T-cells) via chemotaxis, bridging innate and adaptive immunity.

The recombinant form is produced using biotechnological platforms (e.g., *E. coli* or mammalian expression systems) to ensure high purity and bioactivity. This allows scalable production for research and therapeutic applications. Studies highlight DEFb1’s dual role: while it protects against infections, dysregulation is linked to chronic inflammation, autoimmune diseases, and cancer progression. For instance, reduced DEFb1 expression correlates with increased susceptibility to urinary tract infections, while overexpression in tumors may influence microenvironment interactions.

Recent research explores recombinant DEFb1’s therapeutic potential, including antimicrobial coatings, wound healing agents, and adjuvants in vaccines. Its ability to enhance epithelial barrier function and modulate immune responses positions it as a candidate for treating infections, inflammatory disorders, and even as a biomarker for certain cancers. However, challenges like stability in physiological conditions and delivery efficiency require further optimization. Understanding DEFb1’s structure-function relationships and signaling pathways (e.g., CCR6 receptor binding) remains critical for advancing its clinical translation.